Celldex Therapeutics lowered its price target from $67 to $61 after stopping its Phase 2 trial for barzolvolimab, a drug for prurigo nodularis, because it failed to meet primary efficacy goals. Despite this setback, the drug showed a strong safety profile, and Celldex has other Phase 3 trials ongoing with results expected in late 2026. The adjusted price target still suggests significant upside potential, reflecting optimism about the company's future growth prospects.
The global automotive pumps market is projected to grow from $31.11 billion in 2026 to $34.15 billion by 2035, at a CAGR of 1.0%. Growth is driven by increased pump content in passenger cars, especially for engine and HVAC systems, as OEMs adopt adva...
Equinor reported mixed Q2 2026 results with earnings per share of $1.33, slightly below analyst expectations of $1.38. However, revenue rose to $34.40 billion, surpassing forecasts due to a 3% production increase and higher energy prices. The company...
Knight-Swift Transportation Holdings is set to report its Q2 earnings on July 22, 2026, with analysts expecting an EPS of $0.51 and revenue of $2.05 billion, reflecting an 8% revenue increase year-over-year. The company benefits from improving freigh...
Liquidnitro Games has appointed Cedrick Collomb, former CTO of Tencent Games Global, as its new Chief Technology Officer following a $19.1 million Series A funding round. Collomb brings extensive industry experience and will lead the company's strate...
Crédit Agricole S.A. has completed the issuance of preferred senior bonds totaling €324.9 million with a fixed interest rate of 3.65%, payable quarterly. The bonds mature between July 2026 and July 2036. This issuance, approved by the French financia...
